Victor Maina, best known for developing the iconic OTC building in Nairobi, continues to shape the city's landscape. The mall ...

Takeda said it would sell selected OTC and prescription products that are ... The announcement followed a report by Nikkei Business that Takeda was seeking to sell its Japan-based consumer health ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

Global Star's securities began trading on OTC Markets as of March 14, 2025. What is the proposed business combination involving Global Star? The proposed business combination is between Global ...

OTC Markets Group announced today that its Board of Directors authorized and approved a quarterly cash dividend of $0.18 per share of Class A Common Stock. The quarterly cash dividend is payable on ...

The former chief financial officer for a not-for-profit that serves adults with disabilities in New Jersey has been charged with stealing $2.5 million from the company.

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Perimeter ...

“Our integrated OTC offering gives clients the ability to ... Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.

NEW YORK--(BUSINESS WIRE)--DriveWealth ... of its overnight trading capabilities through a collaboration with OTC Markets Group Inc. (OTCQX: OTCM), an operator of regulated markets for U.S ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced PINEWOOD ...

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Anaergia Inc ...

PHILADELPHIA--(BUSINESS WIRE)--iECURE ... today announced that initial data from the Phase 1/2 OTC-HOPE clinical trial evaluating in vivo gene editing candidate ECUR-506 in neonatal onset ...